Insmed, Inc.
(NASDAQ : INSM)

( )
INSM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -13.49%265.330.0%$3803.52m
BNTXBioNTech SE -18.67%279.830.0%$1221.54m
NVAXNovavax, Inc. -11.60%141.8678.2%$678.26m
AMGNAmgen, Inc. 3.14%208.791.4%$636.09m
GILDGilead Sciences, Inc. -0.09%69.501.0%$509.20m
LGVNLongeveron Inc. 0.65%20.250.0%$468.87m
VRTXVertex Pharmaceuticals, Inc. 0.61%205.061.9%$451.31m
REGNRegeneron Pharmaceuticals, Inc. -1.60%625.002.7%$399.60m
ILMNIllumina, Inc. 1.26%351.653.3%$324.62m
SNSSSunesis Pharmaceuticals, Inc. 2.68%4.210.7%$294.29m
BIIBBiogen, Inc. 0.09%224.111.8%$281.34m
SGENSeagen Inc. -3.14%146.015.8%$152.04m
INCYIncyte Corp. -1.17%65.012.4%$146.25m
EXASEXACT Sciences Corp. 5.55%80.8418.0%$141.11m
BMRNBioMarin Pharmaceutical, Inc. 1.56%84.244.2%$134.04m

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.